In a study of 179 patients, Lee et al. found that the CRC patients with KRAS mutations had significantly higher standardized uptake value (SUV max) and SUV peak values than the patients expressing wild-type KRAS mutations [59]. Here, KRAS is linked to colorectal carcinoma.